Research analysts at HC Wainwright dropped their Q1 2025 EPS estimates for AnaptysBio in a research report issued on ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio (NASDAQ:ANAB – Free Report) had its price target boosted by Wells Fargo & Company from $40.00 to $51.00 in a report issued on Thursday,Benzinga reports. Wells Fargo & Company currently has ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...